4 completed, 2 unknown, 1 withdrawn. 7 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 4, Unknown 2, Withdrawn 1 |
| Phase 2 | 3 | Unknown 2, Withdrawn 1 |
Follow Effects of Immunotherapy: new trials by email Literature Review of Effects of Immunotherapy trials Research Report on Effects of Immunotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| TIL and Anti-PD1 in Metastatic Melanoma Nivolumab & Tumor Infiltrating Lymphocytes with/without Interferon-Alpha - Toxicity, Drug, Adverse Drug Event | Phase 1 / Phase 2 | Unknown | Leiden University | 34 | 2018-07-31 | 2023-12-12 |
| Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma Anti-GD2 CART - Neuroblastoma, Effects of Immunotherapy | Phase 1 | Completed | Zhujiang Hospital | 12 | 2016-01-01 | 2024-03-15 |
| Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer Axalimogene filolisbac - Effects of Immunotherapy, Metastatic/Recurrent Cervical Cancer | Phase 1 | Completed | Advaxis, Inc. | 12 | 2015-03-04 | 2024-05-20 |
| Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma Stereotactic body radiotherapy (SBRT), Ipilimumab - Melanoma, Effects of Immunotherapy | Phase 1 | Completed | Radiotherapie | 13 | 2015-03-01 | 2017-01-10 |
| Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma GeniusVac-Mel4 - Melanoma, Tumor Vaccines | Phase 1 | Completed | University Hospital, Grenoble | 9 | 2013-06-01 | 2025-08-13 |
| Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) - Acute Myelogenous Leukemia, Myeloid Leukemia in Remission | Phase 1 / Phase 2 | Unknown | Jules Bordet Institute | 20 | 2011-12-01 | 2012-01-20 |
| SCH708980 With and Without AmBisome for Visceral Leishmaniasis SCH708980 Anti-IL-10 monoclonal, AmBisome - Leishmaniasis, Effects of Immunotherapy | Phase 1 / Phase 2 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2013-08-28 |
Melanoma (3) · Adenocarcinoma (1) · Carcinoma (1) · Carcinoma, Adenosquamous (1) · Carcinoma, Small Cell (1) · Carcinoma, Squamous Cell (1) · Drug-Related Side Effects and Adverse Reactions (1) · Genital Diseases, Female (1) · Genital Neoplasms, Female (1) · Leishmaniasis (1) · Leukemia, Myeloid, Acute (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1)
Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms, Germ Cell and Embryonal (4) · Neoplasms, Nerve Tissue (4) · Neuroectodermal Tumors (4) · Skin Diseases (4) · Skin and Connective Tissue Diseases (4) · Neoplasms by Site (3) · Neuroendocrine Tumors (3) · Nevi and Melanomas (3) · Skin Neoplasms (3) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Chemically-Induced Disorders (1) · Euglenozoa Infections (1)
Ipilimumab (1) · Nivolumab (1) · Radiosurgery (1) · liposomal amphotericin B (1)
Advaxis, Inc. (1) · Jules Bordet Institute (1) · Leiden University (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Radiotherapie (1) · University Hospital, Grenoble (1) · Zhujiang Hospital (1)
Belgium (2) · China (1) · France (1) · India (1) · Netherlands (1) · United States (1)
David Sacks, PhD (1) · Ellen Kapiteijn, Dr. (1) · Joel Plumas, PhD (1) · Julie Charles, MD, PhD (1) · Lihua Yang, M.D., Ph.D. (1) · Lung-Ji Chang, Ph.D. (1) · Philippe Martiat, MD PhD (1) · Piet Ost, MD, PhD (1) · Shyam Sundar, MD (1)